Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: Application to clinical pharmacokinetic studies with oxaliplatin

Journal of Pharmaceutical and Biomedical Analysis

Volumn 24, Issue 1, 2000, Pages 1-10

  Morrison, J Gilmour ^a   White, Peter ^a   McDougall, Sophie ^a   Firth, John W ^a   Woolfrey, Steve G ^a   Graham, Martin A ^b   Greenslade, Dennis ^a  

^a Alnwick Research Centre   (United Kingdom)

^b Sanofi Synthélabo ^*  (United States)

Author keywords

Assay validation; Inductively coupled plasma mass spectrometry; Oxaliplatin; Pharmacokinetics; Platinum; Ultrasonic nebulisation

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOHEXYLAMINE DERIVATIVE; FLUOROURACIL; OXALIPLATIN; PLATINUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BODY FLUID; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; HUMAN; LONG TERM EXPOSURE; NEBULIZATION; PRIORITY JOURNAL; ULTRAFILTRATION; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; HUMAN; ORGANOPLATINUM COMPOUNDS; PLATINUM; SENSITIVITY AND SPECIFICITY; SPECTRUM ANALYSIS, MASS;

EID: 0034578672     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(00)00377-0     Document Type: Article

References (14)

1. M.J. McKeage, Drug Safety 13 (4) (1995) 228-244.
2. W.A.J. De Waal, F.J.M.J Maessen, J.C. Kraak, J. Pharm. Biomed. Anal. 8 (1990) 1-30.
3. J. Kern, B. Braess, C.C. Bottger, W. Kaufmann, S. Hiddemann, E. Schleyer, Clin. Cancer Res. 5 (1999) 761-765.
4. J.G. Morrison, D. Bissett, I.F.D. Stephens, et al., Int. J. Cancer 2 (1993) 33-37.
5. G. Holland, S.D. Tanner, Plasma Source Mass Spectrometry, MPG Books, Bodmin, 1999, pp. 255-285.
6. P. Tothill, L.M. Matheson, J.F. Smyth, K. McKay, J. Anal. Atomic Spec. 5 (1990) 619-622.
7. E. Gamelin, P. Allain, P. Maillart, et al., Cancer Chemother. Pharmacol. 37 (1995) 97-102.
8. A. Johnsson, H. Bjork, A. Shultz, T. Skarby, Cancer Chemother. Pharmacol. 41 (1998) 248-251.
9. E. Gamelin, M. Boisdron-Celle, A. Lebouil, et al., Anti-Cancer Drugs 9 (1998) 223-228.
10. V.P. Shah, K.K. Midha, S.V. Dighe, Pharm. Res. 9 (1992) 588-592.
11. P. Workman, M.A. Graham, Cancer surveys, Pharmacokinet. Cancer Chemother. 17' (1993) 123-156.
12. P. Allain, S. Berre, Y. Mauras, A. Le Bouil, Biol. Mass. Spec. 21 (1992) 141-143.
13. P.J. Webster, P. Snitch, S.L. Jones, N. Amos, P.R. Harnett, J. Oncol. Pharm. Pract. 1 (1995) 41-48.
14. E. Gamelin, A. Le Boul, M. Boisdron-Celle, Clin. Cancer Res. 3 (1997) 891-899.